Optimization of a Colorimetric Assay to Determine Lactate Dehydrogenase B Activity Using Design of Experiments.


Journal

SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 17 9 2020
medline: 1 3 2022
entrez: 16 9 2020
Statut: ppublish

Résumé

Lactate dehydrogenase B (LDH-B) is overexpressed in lung and breast cancer, and it has been considered as a potential target to treat these types of cancer. Herein, we propose a straightforward incomplete factorial (IF) design composed of 12 combinations of two reaction buffers, three pH values, three salt (NaCl) concentrations, and three incubation times, which we called IF-BPST (Buffer/pH/Salt/Time), for the optimization of a colorimetric LDH-B assay in a final volume of 100 µL using 96-well plates. The assay is based on the absorbance change at ~570 nm and the color change of the reaction mixture due to the release of NADH that reacts with nitroblue tetrazolium (NBT) and phenazine methosulfate (PMS), resulting in the formation of a blue-purple formazan. The results obtained using the IF-BPST were comparable with those obtained by response surface methodology. Our work revealed that the NBT/PMS assay with some modifications can be used to measure the activity of LDH-B and other dehydrogenases in a high-throughput screening format at the early stages of drug discovery. LDH-B containing lysates cannot be assayed directly, however, due to the sensitivity of the method toward detergents. Thus, we suggest precipitating the proteins in the lysates to remove the interfering detergents, and then to dissolve the protein pellet in a suitable buffer and carry out the assay.

Identifiants

pubmed: 32935604
doi: 10.1177/2472555220956589
pii: S2472-5552(22)06684-9
doi:

Substances chimiques

Buffers 0
Formazans 0
Isoenzymes 0
NAD 0U46U6E8UK
Nitroblue Tetrazolium 298-83-9
Methylphenazonium Methosulfate 299-11-6
Sodium Chloride 451W47IQ8X
L-Lactate Dehydrogenase EC 1.1.1.27
lactate dehydrogenase 1 EC 1.1.1.27.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-399

Auteurs

Christos Papaneophytou (C)

Department of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus.

Maria-Elli Zervou (ME)

Department of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus.

Anastasis Theofanous (A)

Department of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH